Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Docetaxel

Nimotuzumab

Cisplatin

Tubulin Modulators

Antimitotic Agents

Antineoplastic Agents, Immunological

Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin, and concurrent weekly Nimotuzumab.

Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin.

Patients received weekly nimotuzumab (200mg, IV) concurrent with chemoradiotherapy.

Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy

docetaxel and cisplatin

daily RT to the chest

Hui Liu, Professor

This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab in combined with chemoradiotherapy for unresectable,local advanced squamous cell lung cancer.

This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab combined with chemoradiotherapy for unresectable,locally advanced squamous cell lung cancer.

All patients were planned to receive radical dose of chest radiation and concurrent chemotherapy of weekly docetaxel and cisplatin, each of 1 day's duration.

Nimotuzumab group was treated with weekly nimotuzumab (200mg, IV) combined with chemoradiotherapy, while control group was treated with chemoradiotherapy.

Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer

A Prospective Randomized Phase Ⅱ Study of Nimotuzumab Combined With Chemoradiotherapy for Unresectable, Locally Advanced Squamous Cell Lung Cancer

rate of grade 3-4 radiation esophagitis as assessed by CTCAE v4.0

rate of grade 3-4 radiation pneumonitis as assessed by CTCAE v4.0

rates of local-regional recurrence, distant metastasis and brain metastasis

Spots Global Cancer Trial Database for daily rt to the chest